Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2011 Oct 17;60(11):2995–3005. doi: 10.2337/db11-0026

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2011 by the American Diabetes Association.

Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. See http://creativecommons.org/licenses/by-nc-nd/3.0/ for details.

PMC Copyright notice

FIG. 7. — pHBSP decreases ischemia at 1 μg/kg and exacerbates preretinal neovascularization in OIR. The murine retinal vasculature was assessed in flat mounts after OIR using isolectin labeling and confocal microscopy. A: Retinal ischemia: pHBSP at 1 μg/kg decreases the ischemic region (***P < 0.001), while the higher doses of 10 and 30 μg/kg have no effect on ischemia. B: Retinal neovascularization: upon quantification of preretinal vessels, pHBSP had no significant effect on neovascularization at any of the doses tested (1, 10, and 30 μg/kg) when compared with the scrambled peptide or PBS control. Data are mean ± SEM; n = 6 per group. PBS, PBS control; Sc, scrambled pHBSP. C and D: Retinal flat mounts showing hyperfluorescent preretinal neovascularization in PBS-treated (C) and 1 μg/kg of pHBSP-treated (D) OIR mice (arrow). (A high-quality color representation of this figure is available in the online issue.)